OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentPhase 2

MHB036C

MHB036C is an antibody-drug conjugate from Minghui Pharmaceutical (Hangzhou) Ltd, in registered phase 2 trials for metastatic cancer.